Etanercept biosimilar - Bio Sidus S.A
Latest Information Update: 16 Aug 2013
Price : $50
At a glance
- Originator Bio Sidus S.A.
- Developer Biosidus S.A.
- Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 15 Aug 2013 Investigation in Rheumatoid arthritis in Argentina (SC)
- 15 Aug 2013 Investigation in Autoimmune disorders in Argentina (SC)